The shedded ectodomain of Lyve-1 expressed on M2-like tumor-associated macrophages inhibits melanoma cell proliferation
Targeting immune cells that support tumor growth is an effective therapeutic strategy in tumor entities such as melanoma. M2-like tumor-associated macrophages (TAM) sustain tumor growth by secreting anti-inflammatory cytokines, proteases and growth factors. In this study, we show that a protein deri...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 10, 2017
|
| In: |
OncoTarget
Year: 2017, Volume: 8, Issue: 61, Pages: 103682-103692 |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.21771 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.18632/oncotarget.21771 Verlag, Volltext: http://www.oncotarget.com/fulltext/21771 |
| Author Notes: | Claudia Dollt, Kathrin Becker, Julia Michel, Susanne Melchers, Cleo-Aron Weis, Kai Schledzewski, Andreas Krewer, Loreen Kloss, Christoffer Gebhardt, Jochen Utikal and Astrid Schmieder |
| Summary: | Targeting immune cells that support tumor growth is an effective therapeutic strategy in tumor entities such as melanoma. M2-like tumor-associated macrophages (TAM) sustain tumor growth by secreting anti-inflammatory cytokines, proteases and growth factors. In this study, we show that a protein derived from M2-like macrophages namely the shedded ectodomain of Lyve-1 (sLyve-1) decreases human HT144 and murine B16F1 melanoma cell proliferation significantly by acting as a decoy receptor for lowmolecular weight hyaluronic acid (LMW-HA) although the LMW-HA/Lyve-1 interaction on lymphatic endothelial cells has been described to induce lymphangiogenesis. This is in line with our finding that the number of LYVE-1+ TAM decreases in higher human melanoma stages and that the early growth of B16 transplant tumors is enhanced in Lyve-1 knockout mice when compared to wild-type mice due to an increased melanoma cell proliferation. LYVE-1 expressing TAM are however true M2 macrophages as they coexpress typical M2-markers such as CD163 and CD206. The results of the present study highlight the necessity to carefully determine the net effect particular TAM subpopulations have on tumors before establishing a treatment to target these immune cells. |
|---|---|
| Item Description: | Gesehen am 12.07.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.21771 |